[The response of peripheral blood lymphocytes from lung cancer patients to in-vitro treatment with recombinant interleukin-2].
The cytotoxic activity of peripheral blood lymphocytes of 135 lung cancer patients was studied. A wide range of cytotoxicity values was shown--from 0 to 88%. During the randomized investigation of these patients no strong correlation was found between the levels of cytotoxicity and the cancer stages. A certain tendency of increasing the number of patients with weak cytotoxic activity upon progressing disease was followed. The lymphocytes with a strong natural killer activity did not react on the in vitro incubation with interleukin-2. The lymphocytes with a strong was obtained when the lymphocytes with the lowest cytotoxicity levels were incubated with this immunomodulator.
Pogodina
O N
ON
Institute of Cytology, Russian Academy of Sciences, St. Petersburg.
Karaseva
N A
NA
Ivanov
V A
VA
D002478:Cells, Cultured; D003470:Culture Media; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D011897:Random Allocation; D011994:Recombinant Proteins / Q000494:pharmacology
D003470:Culture Media; D007376:Interleukin-2; D011994:Recombinant Proteins
Izuchenie otveta limfotsitov perifericheskoĭ krovi bol'nykh rakom legkogo na obrabotku in vitro rekombinantnym interleĭkinom-2.